Literature DB >> 30590056

Dissecting Effects of Anti-cancer Drugs and Cancer-Associated Fibroblasts by On-Chip Reconstitution of Immunocompetent Tumor Microenvironments.

Marie Nguyen1, Adele De Ninno2, Arianna Mencattini3, Fanny Mermet-Meillon1, Giulia Fornabaio1, Sophia S Evans1, Mélissande Cossutta1, Yasmine Khira1, Weijing Han1, Philémon Sirven4, Floriane Pelon5, Davide Di Giuseppe3, Francesca Romana Bertani6, Annamaria Gerardino6, Ayako Yamada7, Stéphanie Descroix7, Vassili Soumelis4, Fatima Mechta-Grigoriou5, Gérard Zalcman8, Jacques Camonis1, Eugenio Martinelli3, Luca Businaro6, Maria Carla Parrini9.   

Abstract

A major challenge in cancer research is the complexity of the tumor microenvironment, which includes the host immunological setting. Inspired by the emerging technology of organ-on-chip, we achieved 3D co-cultures in microfluidic devices (integrating four cell populations: cancer, immune, endothelial, and fibroblasts) to reconstitute ex vivo a human tumor ecosystem (HER2+ breast cancer). We visualized and quantified the complex dynamics of this tumor-on-chip, in the absence or in the presence of the drug trastuzumab (Herceptin), a targeted antibody therapy directed against the HER2 receptor. We uncovered the capacity of the drug trastuzumab to specifically promote long cancer-immune interactions (>50 min), recapitulating an anti-tumoral ADCC (antibody-dependent cell-mediated cytotoxicity) immune response. Cancer-associated fibroblasts (CAFs) antagonized the effects of trastuzumab. These observations constitute a proof of concept that tumors-on-chip are powerful platforms to study ex vivo immunocompetent tumor microenvironments, to characterize ecosystem-level drug responses, and to dissect the roles of stromal components.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HER2(+) breast cancer; cancer-associated fibroblasts; immunotherapy; live cell imaging; microfluidics; organ-on-chip; pre-clinical models; trastuzumab; tumor microenvironment; tumor-on-chip

Mesh:

Substances:

Year:  2018        PMID: 30590056     DOI: 10.1016/j.celrep.2018.12.015

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  31 in total

1.  Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.

Authors:  Ioannis A Vathiotis; Myrto K Moutafi; Prajan Divakar; Thazin Nwe Aung; Tao Qing; Aileen Fernandez; Vesal Yaghoobi; Sarra El-Abed; Yingbo Wang; Sebastien Guillaume; Paolo Nuciforo; Jens Huober; Serena Di Cosimo; Sung-Bae Kim; Nadia Harbeck; Henry Gomez; Saba Shafi; Konstantinos N Syrigos; George Fountzilas; Christos Sotiriou; Lajos Pusztai; Sarah Warren; David L Rimm
Journal:  Clin Cancer Res       Date:  2021-08-31       Impact factor: 12.531

Review 2.  Engineering Microphysiological Immune System Responses on Chips.

Authors:  Chris P Miller; Woojung Shin; Eun Hyun Ahn; Hyun Jung Kim; Deok-Ho Kim
Journal:  Trends Biotechnol       Date:  2020-02-18       Impact factor: 19.536

Review 3.  Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers.

Authors:  Farbod Amirghasemi; Emmanuela Adjei-Sowah; Barbara A Pockaj; Mehdi Nikkhah
Journal:  Ann Biomed Eng       Date:  2021-01-05       Impact factor: 3.934

Review 4.  Tumor microenvironment as a therapeutic target in cancer.

Authors:  Yi Xiao; Dihua Yu
Journal:  Pharmacol Ther       Date:  2020-11-28       Impact factor: 12.310

Review 5.  Breast tumor-on-chip models: From disease modeling to personalized drug screening.

Authors:  Bano Subia; Ujjwal Ranjan Dahiya; Sarita Mishra; Jessica Ayache; Guilhem Velve Casquillas; David Caballero; Rui L Reis; Subhas C Kundu
Journal:  J Control Release       Date:  2021-01-06       Impact factor: 9.776

Review 6.  Microfluidic technologies for immunotherapy studies on solid tumours.

Authors:  K Paterson; S Zanivan; R Glasspool; S B Coffelt; M Zagnoni
Journal:  Lab Chip       Date:  2021-06-15       Impact factor: 6.799

Review 7.  Engineered in vitro tumor models for cell-based immunotherapy.

Authors:  Yuta Ando; Chelsea Mariano; Keyue Shen
Journal:  Acta Biomater       Date:  2021-04-20       Impact factor: 10.633

8.  A Hybrid In Silico and Tumor-on-a-Chip Approach to Model Targeted Protein Behavior in 3D Microenvironments.

Authors:  Valentina Palacio-Castañeda; Simon Dumas; Philipp Albrecht; Thijmen J Wijgers; Stéphanie Descroix; Wouter P R Verdurmen
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

9.  Combining microfluidics with machine learning algorithms for RBC classification in rare hereditary hemolytic anemia.

Authors:  Valeria Rizzuto; Arianna Mencattini; Begoña Álvarez-González; Davide Di Giuseppe; Eugenio Martinelli; David Beneitez-Pastor; Maria Del Mar Mañú-Pereira; Maria José Lopez-Martinez; Josep Samitier
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

10.  Discovering the hidden messages within cell trajectories using a deep learning approach for in vitro evaluation of cancer drug treatments.

Authors:  A Mencattini; D Di Giuseppe; M C Comes; P Casti; F Corsi; F R Bertani; L Ghibelli; L Businaro; C Di Natale; M C Parrini; E Martinelli
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.